Evidence map›Paper›PMID 39681656›Full record

ArticleScientific reports2024

Protective effect of interferon type I on barrier function of human airway epithelium during rhinovirus infections in vitro.

Helena Boland, Adrian Endres, Ralf Kinscherf, Ralf Schubert, Beate Wilhelm, Hans Schwarzbach, Danny Jonigk, Peter Braubach, Gernot Rohde, Carla Bellinghausen

Abstract read
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Helena BolandDepartment of Respiratory Medicine and Allergology, Medical Clinic 1, University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany.
Adrian EndresDepartment of Respiratory Medicine and Allergology, Medical Clinic 1, University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany.
Ralf KinscherfDepartment of Medical Cell Biology, Institute for Anatomy and Cell Biology, University of Marburg, Marburg, Germany.
Ralf SchubertDivision of Pediatrics, Pulmonology, Allergology, Infectious Diseases and Gastroenterology, Children's Hospital, University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany.
Beate WilhelmDepartment of Medical Cell Biology, Institute for Anatomy and Cell Biology, University of Marburg, Marburg, Germany.
Hans SchwarzbachDepartment of Medical Cell Biology, Institute for Anatomy and Cell Biology, University of Marburg, Marburg, Germany.
Danny JonigkInstitute for Pathology, UKA University Medical Center RWTH University Aachen, Aachen, Germany.
Peter BraubachInstitute of Pathology, Hannover Medical School, Hanover, Germany.
Gernot RohdeDepartment of Respiratory Medicine and Allergology, Medical Clinic 1, University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany.
Carla BellinghausenDepartment of Respiratory Medicine and Allergology, Medical Clinic 1, University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany. c.bellinghausen@med.uni-frankfurt.de.ORCID 0000-0001-8025-2846

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The airway epithelium provides a crucial barrier against infection with respiratory pathogens. This barrier can be impaired following viral infection, paving the way for bacterial superinfections. Type I interferons (IFNs) are important antiviral mediators, and inhaled formulations of these glycoproteins are considered a potential approach for the treatment of respiratory viral infections. To investigate if type I IFNs can also protect against virus-induced epithelial barrier dysfunction, differentiated primary bronchial epithelial cells were pre-treated with IFN-β1a and subsequently infected with human rhinovirus (HRV) for 24 to 72h. Moreover, to functionally assess the effects of IFN-β1a pre-treatment on barrier integrity, we conducted co-infection experiments, in which cells were initially infected with HRV, and superinfected with Streptococcus pneumoniae 24 to 72 h later. In untreated cells, HRV infection significantly damaged ZO-1 positive tight junctions and cilia, and transiently increased permeability, whereas the barrier of cultures pre-treated with IFN-β1a remained intact. In co-infection experiments, bacteria were able to penetrate deeper into the cell layers of HRV-infected cultures than into those of uninfected cells. IFN-β1a pre-treatment abrogated virus-induced damage to the epithelial barrier. Taken together, these data demonstrate a beneficial effect of IFN-β in protecting epithelial barrier function in addition to its antiviral effects.

Indexed as

Epithelial CellsInterferon Type IPicornaviridae InfectionsRhinovirusTight JunctionsBronchiCells, CulturedCiliaCoinfectionHumansRespiratory MucosaStreptococcus pneumoniaeZonula Occludens-1 ProteinInterferon Type IZonula Occludens-1 Protein

Identifiers

PMID39681656
PMCPMC11649702

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.